Results
A total of 152 subjects from the AIM-HIGH MRI substudy were included in the analysis after excluding subjects with insufficient image quality or missing clinical measurements as shown by the flowchart of subject inclusion/exclusion in Figure 1 . Subjects were 45 to 79 years old (median, 62), with 81% male, 12% nonwhite, 26% current smokers, 27% with a history of diabetes mellitus, and 82% with a history of hypertension (Table 1) . Median total cholesterol, LDL-C, HDL-C (high-density lipoprotein cholesterol, triglycerides, and Lp(a) at baseline were 145, 72, 35, 162, and 32 nmol/L, respectively. Baseline percent wall volume (%WV) ranged from 28% to 60% (median, 40%; SD, 7.1%). Most baseline variables were distributed similarly in the monotherapy and combination therapy arms (Table 1) , though the monotherapy group had more white subjects (P=0.025) and lower Lp(a) (P=0.020) than the combination therapy group. Table 3 . Only Lp(a) at baseline (β=0.33 per 1-SD increase; 95% confidence interval [CI], 0.15-0.51; P=0.001) and on study (β=0.31; 95% CI, 0.13-0.49; P=0.001) were significantly associated with plaque progression at the Bonferroni-corrected level α=0.0036. Baseline (β=0.34 per 1-SD increase; 95% CI, 0.15-0.52; P<0.001) and on-study Lp(a) (β=0.33; 95% CI, 0.15-0.52; P<0.001) remained independently associated with plaque progression after further adjustment for LDL-C, HDL-C, and triglycerides. The difference between baseline and on-study Lp(a) was not significantly associated with plaque progression (P=0.75). Figure 2 presents an MRI example of carotid plaque progression with elevated Lp(a) at both baseline (263.6 nmol/L) and on study (159.4 nmol/L), other on-study lipids were well controlled, and particularly, on-study LDL-C was 45 mg/dL.
Clinical risk factors and other lipid values between subjects with higher baseline Lp(a) (≥median of 32 nmol/L) and lower baseline Lp(a) (<32 nmol/L) were compared (Table III in the online-only Data Supplement). Nonwhite subjects were more likely to have elevated Lp(a) (P=0.048). Those with higher Lp(a) at baseline tended to have lower total cholesterol (P=0.030), LDL-C (P=0.043), and triglycerides (P=0.048) at 1 year. Baseline %WV was similar between the 2 groups (median, 40% versus 41%; P=0.52), and there was no significant correlation between %WV and baseline Lp(a) (Spearman ρ=−0.04; P=0.60).
Discussion
Our study showed that despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid MRI. Previous studies 10, 11 have demonstrated that progression of carotid plaque volume as assessed by 3-dimensional ultrasound significantly predicted cardiovascular events including stroke, transient ischemic attack, myocardial infarction, and death. van Engelen et al 11 showed that subjects with >10% of carotid plaque progression over 1 year were considered to have an increased risk for future events. However, the clinical implication of the observed carotid atherosclerosis progression at mean 0.2% and up to 3.7% per year as assessed by MRI would require further investigations.
Unlike earlier imaging studies that have demonstrated combinations of lipid therapies with statin, niacin, and bile acid sequestrants lead to regression or slow progression of atherosclerosis either in coronary arteries [12] [13] [14] [15] or in carotid, 16, 17 there was no significant difference in carotid atherosclerosis progression between the 2 treatment groups in AIM-HIGH. This inconsistency may be potentially attributed to several important differences between the earlier studies and AIM-HIGH. First, patients in AIM-HIGH have been treated with statins and had a mean LDL-C of 74 mg/dL at baseline, whereas subjects in earlier studies were lipid treatment naive or with higher LDL-C levels. Second, AIM-HIGH compared the combination therapy to statin, not to placebo as in most earlier studies. By the AIM-HIGH study design, the difference in achieved LDL-C between treatment arms on study was small, 62 mg/dL in the simvastatin plus extended-release niacin group and 67 mg/dL in the simvastatin plus placebo group. Finally, maximum cardiovascular benefits from niacin are associated with a significant decrease of triglyceride-rich very-low-density lipoprotein particles, their remnants, and dense LDL particles 18 ; however, the AIM-HIGH subjects did not have high triglycerides at baseline (a mean of 161 mg/dL). More importantly, the current study results indicate that carotid atherosclerosis continues to progress despite LDL-C lowering to 62 mg/dL and lower LDL-C target is needed to stop or reverse atherosclerosis progression as demonstrated in GLAGOV (Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound) 19 showing that adding evolocumab to statin therapy further lowers LDL-C to a mean of 36.6 mg/dL and reduces coronary atheroma burden.
Importantly, we found that elevated Lp(a) levels were independent predictors of increases in carotid atherosclerosis burden. This finding is consistent with observations from other AIM-HIGH 6 and epidemiological and genetic association studies showing a continuous and independent association between Lp(a) and CVD. 3, 4, 20, 21 In AIM-HIGH, Lp(a) levels were predictive of residual CVD risk with baseline and on-study Lp(a) levels being significantly associated with CVD events both in the statin group (baseline hazard ratio, 1.24; P=0.002 and on-study hazard ratio, 1.21; P=0.017) and in the statin+extended-release niacin group (baseline hazard ratio, 1.25; P=0.001 and on-study hazard ratio, 1.18; P=0.028), suggesting that elevated Lp(a) levels continue to impact CVD risk in patients on intensive lipid therapy with well-treated LDL-C levels. 6 In a meta-analysis of 18 population studies, Danesh et al 1 demonstrated that compared with the group with the bottom third of Lp(a) levels, the group with the top third had a hazard ratio of 1.6 (95% CI, 1.41-1.8) for coronary heart disease death or nonfatal myocardial infarction. Many hypothesized mechanisms have been proposed for the contributions of Lp(a) to atherothrombotic vascular diseases, including impairing fibrinolysis, promoting cell recruitment to vessel wall, acceleration of macrophage form cell formation, and contributing to increased levels of proinflammatory oxidized phospholipids. [22] [23] [24] [25] There have been mixed reports on the association of Lp(a) levels with atherosclerosis burden and progression. In a cohort of young stroke patients, Nasr et al 5 showed that for each SD increase in Lp(a), the risk of carotid atherosclerosis increased significantly in the second and third tertiles of Lp(a) compared with the first (odds ratio, 1.89 and 2.96, respectively). We previously reported that Lp(a) was positively associated with high-risk plaque features including intraplaque hemorrhage, mural thrombus, or surface defects 7 and with plaque vascularity 
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Treatment with extended-release niacin significantly lowered Lp(a) levels by 21% in the AIM-HIGH main trial 9 and 25% in the carotid MRI substudy cohort; this reduction did not translate into reduction in CVD events 9 or atherosclerosis progression. A similar Lp(a) reduction can be achieved with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition using evolocumab and alirocumab, with 25.5% achieved in OSLER (Open Label Study of Long Term Evaluation Against LDL-C Trial) 27 29 showed significant CVD event reduction in patients with CVD and receiving statin therapy, Lp(a) reduction by evolocumab did not add apparent benefit to LDL-C lowering in a population with low Lp(a) at baseline. 29 Whether Lp(a) lowering with PCSK9 inhibition independently contributes to the reductions of coronary atherosclerosis and CVD events in patients with elevated Lp(a) remains unknown. On the other hand, aggressive lowering Lp(a) levels by 73% with apheresis in addition to statin therapy has been shown to provide incremental CVD event reduction in subjects with established vascular disease. 30 Promising result from the recent development in antisense therapy by inhibiting apo(a) mRNA translation showed that Lp(a) can be decreased by >80%. 31 Future studies are needed to determine the potential of aggressively lowering Lp(a), in addition to LDL-C reduction, on atherosclerosis burden and CVD event risk. †Variable was log-transformed before inclusion in the model to reduce right skewness.
Finally, in this hypothesis-generating analysis, although we found a significant association between Lp(a) and plaque growth, we did not find significant association between baseline Lp(a) levels and baseline carotid atherosclerosis burden. This could be because AIM-HIGH participants were enrolled with established CVD, reducing the range of plaque burden of subjects at baseline.
This study has several limitations. The MRI substudy cohort had several differences compared with the entire AIM-HIGH cohort, potentially limiting the generalizability of these results to the broader population. However, while statistically significant, the actual differences in median age (2 years), race (4%), and body mass index (1 kg/m 2 ) were relatively small in absolute terms. More notable is that those in the MRI substudy were less likely than the remainder of the AIM-HIGH cohort to be diabetic (27% versus 34%), potentially because estimated glomerular filtration rate >60 mL min −1 1.73 m −2 was required because of the injection of a gadolinium-based contrast agent. The MRI substudy was also much more likely to be hypertensive (82% versus 71%), though the reason for this is unclear. Within the MRI substudy cohort, there was an imbalance in Lp(a) levels at baseline between the mono and combination therapy groups, which was mitigated by adjusting for treatment group throughout the analysis. Last, of the lipid variables, Lp(a) was the only one found to be significantly associated with %WV change. It is possible that the sample size of 152 subjects afforded insufficient statistical power to detect associations with other lipid variables, so they should be further evaluated in larger studies.
In conclusion, in patients under intensive LDL-C lowering to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid MRI. Elevated Lp(a) levels independently predicted carotid atherosclerosis progression.
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The carotid magnetic resonance imaging (MRI) substudy was funded by R01 HL088214. MRI coils were provided by GE Healthcare and Philips Healthcare. lipoprotein(a) ). Top, Six consecutive postcontrast T1-weighted images (2 mm thickness) of the left common carotid artery up to the bifurcation. Lower, Matching locations 2 y later and a noticeable plaque volume progression as indicated by the yellow arrows compared with baseline. This example is from an AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) participant who was a current smoker, had a history of coronary artery disease with a prior coronary bypass surgery, and on standard of care for secondary prevention, including statin therapy >5 y before enrollment in the study. At baseline, body mass index (BMI)=30, blood pressure=112/70 mm Hg, total cholesterol=140 mg/dL, triglycerides=203 mg/dL, LDL-C (low-density lipoprotein cholesterol)=64 mg/ dL, HDL-C (high-density lipoprotein cholesterol)=35 mg/dL, ApoB (apolipoprotein B)=92 mg/dL, apo A1 (apolipoprotein A1)=120 mg/dL, Lp(a)=263.6 nmol/L (>95 percentile of Lp(a) distribution). The subject was randomized to simvastatin and placebo for extend-release niacin in AIM-HIGH. On-study lipids showed that total cholesterol=115 mg/dL, triglycerides=148 mg/dL, LDL-C=45 mg/dL, HDL-C=40 mg/ dL, ApoB=64 mg/dL, Apo A1=130 mg/dL, Lp(a)=159.4 nmol/L (>90 percentile of Lp(a) distribution).
